Rong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rong Wang has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Thibaud Damy
Dept. of Cardiology, Hôpitaux Universitaires Henri Mondor, AP-HP, Université Paris Est Créteil (UPEC), CEPIA team INSERM U955 ; F-CRIN GRACE, 94000 Créteil
5 shared publications - Carmen Munteanu4 shared publications
- Denis Keohane
Pfizer Inc., 235 E 42nd St, New York, NY 10017, USA
4 shared publications - Eduardo Villacorta
Department of Cardiology, Complejo Asistencial Universitario de Salamanca, P°. de San Vicente 58, 37007 Salamanca, Spain
4 shared publications - Francesco Cappelli
Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy
4 shared publications - Kristen Hsu
13Amyloidosis Research Consortium, Newton, MA
4 shared publications
Latest Publications
- 10 May 2024
- Published by Morressier GmbH
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy PC94 (#15)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 10 May 2024
- Published by Morressier GmbH
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy PC94 (#15)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of burden in caregivers to patients with untreated transthyretin amyloid cardiomyopathy PC33 (#7)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of burden in caregivers to patients with untreated transthyretin amyloid cardiomyopathy PC33 (#7)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Caregiver burden by severity of patient’s heart failure due to transthyretin amyloid cardiomyopathy: results from a large, non-interventional, real-world study PC32 (#6)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Caregiver burden by severity of patient’s heart failure due to transthyretin amyloid cardiomyopathy: results from a large, non-interventional, real-world study PC32 (#6)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction PC95 (#17)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction PC95 (#17)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Burden of transthyretin amyloid cardiomyopathy in treatment-naïve patients by heart failure severity: results from a large, non-interventional, real-world study PC30 (#4)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Burden of transthyretin amyloid cardiomyopathy in treatment-naïve patients by heart failure severity: results from a large, non-interventional, real-world study PC30 (#4)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction PB48 (#3)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction PB48 (#3)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy: post hoc analysis of an international survey study PC31 (#5)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy: post hoc analysis of an international survey study PC31 (#5)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- Open Access
- 23 March 2024
- Published by Springer Nature in Cardiology and Therapy
- Vol. 13 (2) , 359-368
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy
Introduction Transthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM), or a mixed phenotype. Tafamidis meglumine (20 mg po qd) is approved in some markets to delay neurologic progression in ATTR-PN, while high-dose tafamidis (80/61 mg po qd) is approved worldwide to reduce cardiovascular mortality and cardiovascular-related hospitalization in ATTR-CM. The objective of this study was to assess the real-world benefit of high-dose tafamidis for delaying neurologic progression in patients with mixed-phenotype variant ATTR-CM (ATTRv-CM). Methods This exploratory, retrospective, observational cohort study evaluated anonymized electronic medical records and included adult patients with mixed-phenotype ATTRv-CM treated with high-dose tafamidis for at least 6 months. Neurologic assessments included the Medical Research Council (MRC) Scale for Muscle Strength, Neuropathy Impairment Score (NIS) muscle weakness subscale, and Polyneuropathy Disability (PND) instrument. Modified body mass index (mBMI) was also assessed. Results Patients (N = 10) started tafamidis treatment an average of 3.8 months after diagnosis, with an average treatment duration of 20.8 months. Seven of 10 patients demonstrated normal muscle strength on the MRC scale throughout the study, and 9 of 10 patients had no decline in muscle strength during the post-treatment period. The NIS muscle weakness subscale score was ≤ 60 for all patients in the study at all time points, suggesting normal function to mild impairment. Six of 10 patients had no change in walking capacity as measured by the PND instrument at pre- and post-assessments, while one-third of patients had a decrease in PND stage (signaling improvement) from pre- to post-assessment. mBMI remained relatively stable throughout the study. Conclusion This is the first real-world study to demonstrate the potential value of high-dose tafamidis for delaying neurologic disease progression in patients with mixed-phenotype ATTRv-CM. The findings underscore the importance of multidisciplinary assessment for patients with ATTR amyloidosis. Trial registration ClinicalTrials.gov: NCT05139680.
- 23 March 2024
- Published by Springer Nature in Cardiology and Therapy
- Vol. 13 (2) , 359-368
Open AccessReal-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy
Introduction Transthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM), or a mixed phenotype. Tafamidis meglumine (20 mg po qd) is approved in some markets to delay neurologic progression in ATTR-PN, while high-dose tafamidis (80/61 mg po qd) is approved worldwide to reduce cardiovascular mortality and cardiovascular-related hospitalization in ATTR-CM. The objective of this study was to assess the real-world benefit of high-dose tafamidis for delaying neurologic progression in patients with mixed-phenotype variant ATTR-CM (ATTRv-CM). Methods This exploratory, retrospective, observational cohort study evaluated anonymized electronic medical records and included adult patients with mixed-phenotype ATTRv-CM treated with high-dose tafamidis for at least 6 months. Neurologic assessments included the Medical Research Council (MRC) Scale for Muscle Strength, Neuropathy Impairment Score (NIS) muscle weakness subscale, and Polyneuropathy Disability (PND) instrument. Modified body mass index (mBMI) was also assessed. Results Patients (N = 10) started tafamidis treatment an average of 3.8 months after diagnosis, with an average treatment duration of 20.8 months. Seven of 10 patients demonstrated normal muscle strength on the MRC scale throughout the study, and 9 of 10 patients had no decline in muscle strength during the post-treatment period. The NIS muscle weakness subscale score was ≤ 60 for all patients in the study at all time points, suggesting normal function to mild impairment. Six of 10 patients had no change in walking capacity as measured by the PND instrument at pre- and post-assessments, while one-third of patients had a decrease in PND stage (signaling improvement) from pre- to post-assessment. mBMI remained relatively stable throughout the study. Conclusion This is the first real-world study to demonstrate the potential value of high-dose tafamidis for delaying neurologic disease progression in patients with mixed-phenotype ATTRv-CM. The findings underscore the importance of multidisciplinary assessment for patients with ATTR amyloidosis. Trial registration ClinicalTrials.gov: NCT05139680.
- 1 May 2020
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 82, 102418
Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy
- 1 May 2020
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 82, 102418
Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy
- Open Access
- 1 April 2020
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 147, 105200
Development and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology
- 1 April 2020
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 147, 105200
Open AccessDevelopment and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology